Essen Bioscience
Financials
Estimates*
| GBP | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|
| Revenues | 6.5m | 9.8m | 14.6m | 16.7m | 24.3m | 27.6m | 1.3m |
| % growth | 48 % | 52 % | 48 % | 14 % | 46 % | 14 % | (95 %) |
| EBITDA | <1m | <1m | <1m | <1m | 1.2m | 1.3m | 3.0m |
| % EBITDA margin | 5 % | 2 % | 3 % | 3 % | 5 % | 5 % | 234 % |
| Profit | <1m | <1m | <1m | <1m | <1m | <1m | 2.3m |
| % profit margin | 3 % | 1 % | 2 % | 2 % | 4 % | 3 % | 184 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Grant | ||
N/A | Seed | ||
$320m Valuation: $320m 24.6x EV/LTM Revenues 1056.9x EV/LTM EBITDA | Acquisition | ||
| Total Funding | - | ||
Recent News about Essen Bioscience
EditEssen BioScience, a subsidiary of Sartorius, specializes in developing and manufacturing advanced instruments, software, reagents, and consumables for real-time live cell imaging and data analysis. Founded in Ann Arbor, Michigan, the company serves life science researchers and scientists globally, providing tools that enable a deeper understanding of live cell behaviors and functions. The company's core products include the Incucyte Live-Cell Analysis System, which allows for continuous live cell imaging and quantitative data analysis, facilitating more efficient and reproducible experiments. Essen BioScience operates in the life sciences market, particularly focusing on early-stage drug discovery and development. The business model revolves around selling high-tech imaging systems, software, and consumables, generating revenue through direct sales, e-commerce, and ongoing customer support services. The company also engages in educational outreach through webinars, publications, and conference exhibitions to promote its innovative platforms and products.
Keywords: live cell imaging, data analysis, life sciences, drug discovery, Incucyte, quantitative analysis, reagents, consumables, real-time insights, scientific research.